Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biotechnology company focused on developing innovative therapies for cancer and other serious diseases, has announced that its CEO and Chairman, Dr. Vuong Trieu, will present at the OTCQB Virtual Investor Conference on August 6, 2026, at 2:30 p.m. ET. During the presentation, investors will have the opportunity to participate in a live question-and-answer session, gaining direct insights into the company's recent progress and strategic direction.
The company plans to highlight several key developments, including the advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort. This milestone underscores Oncotelic's commitment to progressing its clinical pipeline. Additionally, the company will discuss the expansion of its European clinical sites, which broadens its operational footprint and enhances its ability to conduct multi-national trials. The validation of its Deciparticle(TM) platform through peer-reviewed publications will also be a focus, demonstrating the scientific credibility of its proprietary drug delivery technology.
Other notable achievements to be showcased include scalable cGMP manufacturing capabilities, which are crucial for transitioning from research to commercial-scale production, and the continued development of its AI-driven drug discovery, robotics, and nanomedicine platforms. These initiatives reflect Oncotelic's multifaceted approach to accelerating drug development while improving patient outcomes.
The presentation is expected to draw attention from investors and industry stakeholders, as it provides a comprehensive update on the company's operational and clinical advancements. For those unable to attend live, the event may offer a recorded version, ensuring broader access to the information presented.
Oncotelic Therapeutics is dedicated to advancing precision medicine, RNA therapeutics, and nanomedicine. Its portfolio includes clinical-stage oncology assets, the proprietary Deciparticle drug delivery technology, AI-enabled drug discovery platforms, and scalable GMP manufacturing capabilities. These integrated technologies aim to streamline the development of novel treatments, potentially addressing unmet medical needs in oncology.
Investors and interested parties can view the full press release for more details at https://nnw.fm/fGHUt. Additionally, the latest news and updates regarding OTLC are available in the company's newsroom at https://nnw.fm/OTLC.
The OTCQB Virtual Investor Conference serves as a platform for public companies to present their investment thesis to a wide audience of investors. Oncotelic's participation highlights its transparency and proactive investor relations strategy, which may foster greater confidence in its long-term vision and execution capabilities.
